BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, tumors carrying BRCA2 inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focus...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Reisländer, Timo, Lombardi, Emilia Puig, Groelly, Florian J., Miar, Ana, Porru, Manuela, Di Vito, Serena, Wright, Benjamin, Lockstone, Helen, Biroccio, Annamaria, Harris, Adrian, Londoño-Vallejo, Arturo, Tarsounas, Madalena
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637138/
https://ncbi.nlm.nih.gov/pubmed/31316060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-11048-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires